Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): Current progress and latest advances Review
| Authors: | Schaff, L.; Nayak, L.; Grommes, C. |
| Review Title: | Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): Current progress and latest advances |
| Abstract: | The incidence of primary central nervous system lymphoma (PCNSL) has steadily increased, particularly in elderly patients. Although highly responsive to first-line chemotherapy and radiotherapy, approximately 50% of patients relapse or become refractory within 1 year. Prognosis following relapse is dismal and no standard salvage therapy exists. Bruton’s tyrosine kinase (BTK), a key regulator of the B-cell receptor (BCR) pathway, has emerged as a promising therapeutic target. The first BTK inhibitor ibrutinib has been evaluated in the relapsed/refractory PCNSL setting, with overall response rates of 51.9%–89.0% and median progression-free survival of 4.6–4.8 months. However, ibrutinib inhibits several kinases in addition to BTK, leading to off-target effects. Second-generation BTK inhibitors have since been developed, which afford greater selectivity for BTK and fewer off-target effects. We review current practices in the diagnosis and evaluation of PCNSL, as well as clinical trials of BTK inhibitors in PCNSL and future developments in PCNSL treatment. © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | treatment outcome; neutropenia; review; cancer recurrence; diarrhea; drug penetration; drug safety; hypertension; nonhuman; clinical trials as topic; skin manifestation; primary central nervous system lymphoma; methotrexate; progression free survival; drug eruption; infection; anemia; protein kinase inhibitor; bleeding; blood toxicity; gastrointestinal symptom; leukopenia; thrombocytopenia; pneumocystis pneumonia; central nervous system tumor; central nervous system neoplasms; hyperglycemia; lymphocytopenia; pneumonia; rash; protein kinase inhibitors; alanine aminotransferase; aspartate aminotransferase; maculopapular rash; kidney injury; cardiovascular disease; blood brain barrier; skin disease; piperidines; drug therapy; atrial fibrillation; lung aspergillosis; hypertriglyceridemia; liver injury; invasive aspergillosis; adenine; interstitial pneumonia; clinical trial (topic); molecularly targeted therapy; piperidine derivative; erythema multiforme; hypertransaminasemia; molecular targeted therapy; procedures; overall response rate; pneumocystosis; bruton tyrosine kinase; off-target effect; ibrutinib; humans; human; agammaglobulinaemia tyrosine kinase; acalabrutinib; bruton tyrosine kinase inhibitor; tirabrutinib; zanubrutinib; btk protein, human; orelabrutinib; bronchopulmonary aspergillosis |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 65 |
| Issue: | 7 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2024-01-01 |
| Start Page: | 882 |
| End Page: | 894 |
| Language: | English |
| DOI: | 10.1080/10428194.2024.2333985 |
| PUBMED: | 38597202 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- MSK corresponding author is Christian Grommes -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work